Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24095912 | 0.94 | FAP (0.40) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL24774254 | 0.93 | FAP (0.39) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL24584968 | 0.93 | FAP (0.39) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL23189216 | 0.93 | FAP (0.39) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL26140860 | 0.93 | FAP (0.39) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL25564557 | 0.92 | FAP (0.38) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL17706450 | 0.91 | SIRT2 (0.41) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL21082516 | 0.90 | FAP (0.39) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL25833845 | 0.90 | FAP (0.40) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL25564601 | 0.90 | FAP (0.37) | FAPSIRT2SIRT1BACE1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330258-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | TUBULIS GMBH (DE) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330258-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | CALCR, BCR, PTH1R | FAP 699/4885SIRT2 4769/4885SIRT1 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.